Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Onco360 Oncology Pharmacy
Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)
October 20, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360® Has Been Selected as a Specialty Pharmacy Partner for INLURIYO™ (imlunestrant)
October 06, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Wayrilz™ (rilzabrutinib)
September 08, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360® Has Been Selected as a Specialty Pharmacy Partner for HERNEXEOS® (zongertinib)
August 20, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
August 13, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)
August 04, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360 Has Been Selected as a National Specialty Pharmacy for Augtyro™ (repotrectinib)
July 07, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for ROMVIMZA™ (vimseltinib)
June 23, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
June 20, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.
June 16, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK
May 12, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics
February 17, 2025
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Vyloy® (zolbetuximab-clzb)
November 26, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Revuforj® (revumenib)
November 20, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Itovebi™ (inavolisib)
November 11, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360® Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra® (tislelizumab-jsgr)
October 04, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
LAZCLUZE™ (lazertinib) Now Available from Onco360 for the First-line Treatment, in Combination with Rybrevant®, of Adult Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Have EGFR Exon 19 Deletions or Exon 21 L858R Mutations
August 30, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for VORANIGO® (vorasidenib)
August 12, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360® Has Been Selected as a National Specialty Pharmacy for crovalimab-akkz
August 05, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
CORRECTION -- Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
July 16, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
July 12, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
OJEMDA™ (tovorafenib) Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) Harboring a BRAF Fusion or Rearrangement, or BRAF V600 Mutation
April 29, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya® (danicopan)
April 08, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360® Celebrates Excellent Patient Care, Reflected by Impressive Net Promoter Score
March 14, 2024
From
Onco360 Oncology Pharmacy
Via
GlobeNewswire
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO® (selinexor)
March 13, 2024
From
Onco360 Oncology Pharmacy
Via
Business Wire
FABHALTA (iptacopan) Now Available from Onco360 as the First FDA-Approved Oral Monotherapy Approved for the Treatment of Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
December 20, 2023
From
Onco360 Oncology Pharmacy
Via
Business Wire
OGSIVEO™ (nirogacestat) Now Available from Onco360 as the First and Only FDA-Approved Treatment for Adults with Progressing Desmoid Tumors Who Require Systemic Treatment
November 30, 2023
From
Onco360 Oncology Pharmacy
Via
Business Wire
TRUQAP™ (capivasertib) Now Available from Onco360
November 29, 2023
From
Onco360 Oncology Pharmacy
Via
Business Wire
FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
November 21, 2023
From
Onco360 Oncology Pharmacy
Via
Business Wire
AKEEGA™ (niraparib and abiraterone acetate) Now Available from Onco360
October 03, 2023
From
Onco360 Oncology Pharmacy
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.